Skip to content

Replimune Group REPL Investment Proceeds

Investment Proceeds at other companies

Immunome logo
ImmunomeIMNM
$0-100%
CG Oncology logo
CG OncologyCGON
$252.85M+26.3%
Erasca, Inc. logo
Erasca, Inc.ERAS
$100.83M
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$83.8M+29.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$162.53M-12.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$79.38M+1,384%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's investment proceeds?
Replimune Group (REPL) reported investment proceeds of $101.77M in Q4 2025.
How has Replimune Group's investment proceeds changed year-over-year?
Replimune Group's investment proceeds increased by 10.0% year-over-year, from $92.5M to $101.77M.
What is the long-term trend for Replimune Group's investment proceeds?
Over 3 years (2022 to 2025), Replimune Group's investment proceeds has grown at a 14.7% compound annual growth rate (CAGR), from $256.25M to $386.48M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.